Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Investor's Business Daily on MSN1h
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy PointsNetflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback